Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even more, reaching $3,593 in the same period. J&J transformed from a conglomerate to focus on pharmaceuticals and medical technology, spinning off consumer health and acquiring new companies. Despite challenges like talc lawsuit settlements and recent acquisitions impacting earnings, the company expects strong growth from oncology and other drug sales, with a clear path to double-digit growth by decade's end. Dividends remain a key part of shareholder returns, though risks to cash flow and dividend growth exist due to debt and settlement costs.
Johnson & Johnson shares are trading at USD 256.23 on Pluang as of Oct 22, 2026 01:31 WIB, down 1.21% in the last day. The stock offers a dividend yield of 2.07%, attracting mostly buyers with 90% of order activity on Pluang. Its market capitalization stands at $625.03 billion, reflecting its significant presence in the health sector.
Johnson & Johnson reported a 96% drop in GAAP net earnings for Q3 due to a one-time legal charge related to talc litigation, but adjusted earnings fell only 7.5%. The company raised its full-year adjusted EPS guidance and maintained a strong dividend...
With 10-year Treasury yields near 5%, three Dividend Kings—Johnson & Johnson, Procter & Gamble, and Altria—stand out by raising dividends for over 50 consecutive years while maintaining low market volatility (low beta). These companies generate stron...
Johnson & Johnson announced that TREMFYA (guselkumab) maintained or improved fistula remission in adults with Crohn's disease through 48 weeks in the Phase 3 FUZION study. The combined fistula remission rate increased from 28% at Week 24 to 35% at We...
Johnson & Johnson reported a solid quarter with 6% sales growth and strong oncology business expansion, despite a slight miss in MedTech. Analysts maintain a bullish outlook with a 12-month price target of $291.60, implying a 15.6% upside from curren...
